Further it states the need for population based studies including both non-atypical and atypical hyperplasia to accurately estimate the risk of progression to cancer.If untreated with hysterectomy, endometrial hyperplasia progresses to adenocarcinoma within 20 years in:

28% of cases with atypia (95% CI, 8.6% to 42.5%), and
about 5% of cases without atypia.The rates are more favorable in cases with simple rather than complex hyperplasia, but as mentioned above this terminology was phased out of the WHO classification in 2014. In patients with samples showing atypia, carcinoma is already present in over 40% of cases. Given this, the aforementioned 28% atypia progression rate may be an underestimate, and the true number may closer to the 42.5% part of the studys remarkably wide confidence interval. Treatment
Treatment of endometrial hyperplasia is individualized, and may include hormonal therapy, such as cyclic or continuous progestin therapy, or hysterectomy. See also
Endometrial intraepithelial neoplasia
Endometrial carcinoma
Hyperplasia

References


== External links ==
Siltuximab (INN, trade name Sylvant; also known as CNTO 328, anti-IL-6 chimeric monoclonal antibody or cCLB8) is a chimeric (made from human and mouse proteins) monoclonal antibody. It binds to interleukin-6. Siltuximab has been investigated for the treatment of neoplastic diseases: metastatic renal cell cancer, prostate cancer, other types of cancer, and for Castlemans disease.On April 23, 2014, siltuximab was FDA approved under the brand name of Sylvant for the treatment of patients with idiopathic multicentric Castleman’s disease (iMCD) who do not have human immunodeficiency virus (HIV) or human herpesvirus-8 (HHV-8). Medical uses
Used for the treatment of idiopathic multicentric Castleman disease (iMCD). Clinical trials
Siltuximab has demonstrated significant efficacy and safety in patients with idiopathic multicentric Castleman disease. Treatment results with Siltuximab in B-cell non-Hodgkins lymphoma are inferior to those obtained in multicentric Castleman disease. Siltuximab has also been evaluated in the treatment ovarian cancer, however the efficacy for this cancer is debatable. In addition, siltuximab has been evaluated for multiple myeloma, but there was an insignificant increase in response rates. Side effects
Siltuximab may lower resistance to infections and should not be administered to patients with severe infections. Siltuximab should be discontinued in patients with severe infusion related reactions, anaphylaxis, severe allergic reactions or cytokine release syndromes.